Updates are available Correction dated 2023-06-27
Click to view Correction: https://doi.org/10.1038/s41596-023-00860-5
-
Authors
Downes, Damien J. http://orcid.org/0000-0002-5034-0869
Smith, Alastair L. http://orcid.org/0000-0001-6330-1407
Karpinska, Magdalena A. http://orcid.org/0000-0002-1516-2083
Velychko, Taras http://orcid.org/0000-0003-4087-3730
Rue-Albrecht, Kevin http://orcid.org/0000-0003-3899-3872
Sims, David
Milne, Thomas A. http://orcid.org/0000-0002-0413-4271
Davies, James O. J. http://orcid.org/0000-0002-4108-4357
Oudelaar, A. Marieke http://orcid.org/0000-0002-4016-6158
Hughes, Jim R. http://orcid.org/0000-0002-8955-7256
-
Funding
Funding for this research was provided by:
Wellcome Trust (106130/Z/14/Z, 204826/Z/16/Z, 098931/Z/12/Z)
RCUK | Medical Research Council (MC_UU_00016/14, MC_UU_00016/6, MR/R008108/1)
Max-Planck-Gesellschaft
- License Information
-
More Information
Article History
Received: 21 June 2021
Accepted: 27 October 2021
First Online: 4 February 2022
Change Date: 27 June 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41596-023-00860-5
Competing interests
: J.R.H. and J.O.J.D. are founders and shareholders of Nucleome Therapeutics. J.R.H., J.O.J.D. and D.J.D. are paid consultants for Nucleome Therapeutics. J.R.H. and J.O.J.D. hold patents for Capture-C (WO2017068379A1, EP3365464B1, US10934578B2) and have a patent application for MCC. T.A.M. is a founding shareholder of OxStem Oncology (a subsidiary company of OxStem Ltd.) and a founding shareholder and paid consultant for Sandymount Therapeutics (a subsidiary company of Dark Blue Therapeutics). The other authors have no competing interests.
